BMS Archive

Plant · Scientific monograph

Echinacea purpurea

Purple coneflower

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Immunological Research, Viral Mechanisms Research, Inflammatory Pathways, Respiratory Research

Research overview

Historical use

Echinacea purpurea was a primary medicinal plant of the Plains Native American peoples, used for more conditions than any other plant — including snake bites, burns, toothache, sore throat, and infections. It was adopted by American Eclectic physicians in the 19th century and became the most-prescribed herbal remedy in the US before antibiotics. Introduced to Germany in the 1930s, it remains Europe's best-selling herbal immune supplement.

Modern research context

Echinacea purpurea is the most extensively studied immunomodulatory herb globally. A 2025 systematic review concludes that Echinacea purpurea, particularly at higher doses (2000 mg/day), may reduce RTI incidence, viral load, and symptom severity in children [3]. Pharmacological research identifies NF-κB, MAPK, JAK/STAT, and Nrf2 as key immunomodulatory pathway targets engaged by Echinacea bioactives [2]. In vitro studies identify alkylamides with potent antiviral activity against rhinovirus and influenza, and IL-8 inhibition [5]. Echinacea extract with caffeic acid suppresses ferrous ion accumulation and mitochondrial dysfunction in COVID-19 pseudovirus-infected cell models [7].

Adverse effects

Most commonly reported: GI upset, nausea, unpleasant taste. Allergic reactions in Asteraceae-sensitive individuals. Pharmacovigilance analysis identifies Echinacea purpurea as associated with serious adverse events in post-marketing surveillance [4] — including rare anaphylaxis. Autoimmune exacerbations possible due to immune stimulation. Risk of CYP450-mediated drug interactions [1].

Contraindications

Contraindicated in autoimmune diseases (lupus, rheumatoid arthritis, multiple sclerosis) and in patients on immunosuppressive therapy (transplant recipients). Contraindicated in progressive systemic diseases (HIV/AIDS, tuberculosis). Avoid with immunosuppressants (cyclosporine, tacrolimus). Caution with CYP450-metabolised drugs [1]. Avoid in Asteraceae allergy. Limit continuous use to 8-10 weeks.

Clinical and phytochemical data

Used part

Aerial parts (flowering herb) and roots; fresh or dried; pressed juice; hydroethanolic extracts

Primary active compounds

  • Alkylamides (isobutylamides — primary immunomodulatory)

  • Caffeic acid derivatives (cichoric acid, caftaric acid, echinacoside)

  • Polysaccharides (arabinoxylan, acidic arabinogalactan)

  • Glycoproteins

  • Flavonoids (quercetin, kaempferol, apigenin)

  • Polyacetylenes

Mechanism of action

Echinacea purpurea exerts immunomodulatory activity through simultaneous engagement of NF-κB, MAPK, JAK/STAT, and Nrf2 signalling pathways [2]. Alkylamides bind to cannabinoid receptor CB2 and modulate macrophage and dendritic cell activity, upregulating innate immune responses. Caffeic acid derivatives (cichoric acid) inhibit hyaluronidase and enhance phagocytosis by activating macrophage respiratory burst activity [8]. Echinacea alkylamides demonstrate direct antiviral activity against rhinovirus and influenza through inhibition of viral replication and suppression of IL-8 inflammatory signalling [5]. Caffeic acid component suppresses mitochondrial ROS production and ferrous ion accumulation in viral infection models [7]. CYP450 enzyme activity is modulated by Echinacea constituents with clinically relevant drug interaction implications [1].

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Alkylamides are the best-characterised pharmacokinetic marker for Echinacea; they are rapidly absorbed from the GI tract with detectable plasma concentrations within 20-30 minutes of oral dosing in animal studies. Caffeic acid derivatives have lower bioavailability due to first-pass degradation.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Alkylamides distribute to immune tissues, lymph nodes, and spleen in animal models, consistent with the documented immunomodulatory effects [2]. CNS distribution is possible given CB2 receptor activity.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Echinacea purpurea modulates CYP450 enzyme activity, as identified in a comprehensive review of 10 herbal species with significant CYP450 interactions [1]. The specific isoforms affected (CYP1A2, CYP3A4) and the magnitude of effect vary across preparations and studies.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Alkylamide metabolites are excreted primarily via renal routes. Half-life of the primary immunomodulatory alkylamides in humans has not been formally established in clinical pharmacokinetic studies.

Safety and interactions

Drug interactions

CYP450 substrates (CYP1A2, CYP3A4): Echinacea purpurea is identified as one of ten clinically significant herbal modulators of CYP450 enzyme activity [1]; co-administration with narrow-therapeutic-index CYP450 substrates requires monitoring. Immunosuppressants (cyclosporine, tacrolimus, mycophenolate): Direct pharmacodynamic antagonism — Echinacea immune stimulation counteracts immunosuppressive therapy; combination is contraindicated. Antifungals and antiretrovirals: Potential CYP450-mediated pharmacokinetic interactions [1]. Pharmacovigilance data confirm serious adverse events associated with Echinacea purpurea use in post-marketing surveillance [4].

Toxicity

Pharmacovigilance analysis identifies Echinacea purpurea in reports of serious adverse events [4], including rare anaphylaxis. GI intolerance is the most common adverse effect in clinical trials. No hepatotoxicity at standard doses. Allergic reactions are the primary clinical concern — severity can range from mild urticaria to anaphylaxis, particularly in Asteraceae-sensitised individuals. Long-term safety data are limited. Paediatric scoping review found promising results for respiratory infections without significant adverse events reported [6].

Special precautions

Pregnancy

Use only with medical supervision. Some preparations have been used in pregnancy, but formal safety data are insufficient. Avoid in the first trimester.

Lactation

Insufficient safety data. Short-term use may be acceptable but is not established. Consult healthcare provider.

Hepatic impairment

CYP450 modulation [1] may be altered in hepatic disease. Monitor drug levels of co-administered CYP450-metabolised medications.

Renal impairment

No formal studies. Alkylamide metabolites renally excreted. Use with caution in severe renal impairment.

Sources and references

  1. [1] - Shanaida M, Oleshchuk O, Shevchuk O et al., "Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility", Current Medicinal Chemistry, 2026, PMID: 41764614
  2. [2] - Espinoza JP, Guajardo V, Rodriguez-Diaz M et al., "Pharmacological Insights and Technological Innovations in Curcuma longa L. and Echinacea purpurea (L.) Moench as Plant-Derived Immunomodulators", Pharmaceuticals, 2026, PMID: 41599692
  3. [3] - Mazi A, Alqahtani RM, "Role of Echinacea in the management and prevention of acute respiratory tract infections in children: A systematic review of the evidence", Journal of Family & Community Medicine, 2025, PMID: 41234257
  4. [4] - Liang CJW, Woerdenbag HJ, Ekhart C et al., "Safety Considerations for Natural Products with Adaptogenic and Immunomodulating Activities", Pharmaceuticals, 2025, PMID: 40872598
  5. [5] - Puchalski K, Gerstel JA, Jimoh A et al., "Effects of Echinacea purpurea and Alkylamides on Respiratory Virus Replication and IL-8 Expression In Vitro", Molecules, 2025, PMID: 39860258
  6. [6] - Bertoni C, Alberti I, Parri N et al., "Phytotherapeutic, Homeopathic Interventions and Bee Products for Pediatric Infections: A Scoping Review", Nutrients, 2025, PMID: 41097214
  7. [7] - Chen BK, Chan CH, Wang CK, "Improvement on Ferrous Ion Accumulation and Mitochondrial Dysfunction in the COVID-19 Pseudovirus-Infected Cell Model by Nutritional Strategy", Life, 2025, PMID: 40566632
  8. [8] - Trivadila T, Iswantini D, Rahminiwati M et al., "Herbal Immunostimulants and Their Phytochemicals: Exploring Morinda citrifolia, Echinacea purpurea, and Phyllanthus niruri", Plants, 2025, PMID: 40265854

Additional source links

Continue browsing